
Researchers at WEHI developed a chemovaccination strategy that uses mosquito-delivered malaria parasites paired with antimalarial drugs to trigger a durable immune response in mice.
The drug compounds WM382 and MK-7602 arrest parasite development at the late liver stage, allowing the immune system to recognize antigens without the subject falling ill.
This method, published in Science, aims to turn natural mosquito bites into ongoing immune boosters, potentially providing broader protection against diverse malaria variants than current vaccines.